Active Ingredient History
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Colorectal Neoplasms (approved 2023)
Adenocarcinoma (Phase 1)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Central Nervous System Diseases (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 1)
Colorectal Neoplasms (Phase 2)
Drug Interactions (Phase 1)
Esophageal Neoplasms (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Meninges (Phase 2)
Neoplasms (Phase 2)
Stomach Neoplasms (Phase 2/Phase 3)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue